Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

P.A. Ascierto, M. Del Vecchio, C. Robert, A. Mackiewicz, V. Chiarion-Sileni, A. Arance, C. Lebbé, L. Bastholt, O. Hamid, P. Rutkowski, C. McNeil, C. Garbe, C. Loquai, B. Dreno, L. Thomas, J.-J. Grob, G. Liszkay, M. Nyakas, R. Gutzmer, J. PikielF. Grange, C. Hoeller, V. Ferraresi, M. Smylie, D. Schadendorf, L. Mortier, I.M. Svane, D. Hennicken, A. Qureshi, M. Maio, Massimo Guidoboni

Research output: Contribution to journalArticlepeer-review

Cite this